Generic drug makers are making greater efforts to disclose more information on their products after years of repeated requests from doctors and medical institutions, which want to better ascertain their quality and stability of their supplies.Ohara Pharmaceutical has been disclosing…
HOME > ORGANIZATION
ORGANIZATION
- Science Council of Japan Calls for Public-Private Partnerships to Spur Development of Psychiatric Disease Treatments
August 9, 2017
- New Chuikyo Doctor Reps Question Drug Pricing Premiums, CEA Plan
July 19, 2017
- EFPIA Japan to Provide 1 Million Yen to Support Patients’ Organizations
July 5, 2017
- Generic Use Rate at 65.5% in FY2016: JGA
June 30, 2017
- JMA Announces Endorsement for Chuikyo Rep Replacements
June 26, 2017
- FPMAJ Weighs Refined Version of “Similar Treatment Comparison” Pricing Method
June 20, 2017
- FPMAJ “Not Opposed” to Company Requirements for Receiving Price Maintenance Premium: Kamoya
June 20, 2017
- Reflecting Results of CEA in NHI Prices at Time of Listing Will Be Difficult: FPMAJ Report
June 20, 2017
- FPMAJ Calls for “Cautious” Discussions on Reduction of Price Band for Generic Drugs
June 19, 2017
- FPMAJ Calls for Maintaining Prices for On-Patent Drugs, Lower Price Reduction Rates in Off-Year Revisions
June 19, 2017
- JGA Appreciates Tweaked Honebuto Text on Generics, 80% Goal Achievable on Production Basis
June 13, 2017
- JMA’s Nakagawa Questions Price Difference for LLPs and AGs, Negative about PhRMA Pitch for AWP Alternatives
June 9, 2017
- Membership of Japan Biosimilar Association to Reach 20 Companies in Near Future
June 7, 2017
- Public, Private Donors Put Up US$200-Plus Million for GHIT’s 2nd-Phase Work
June 5, 2017
- Japan Drug Market Could Shrink at CAGR of -2.5% If Price Maintenance Premium Scrapped: EFPIA
June 1, 2017
- JGA Ups Its Lobbying Efforts to Prevent Further Reduction in Price Bands for Generics
June 1, 2017
- Maker FTC Sanctions Member Company for Violating Fair Competition Code
May 30, 2017
- Wholesale Industry FTC to Discuss Prohibiting Free-of-Charge Inventory Transfers between Pharmacies
May 30, 2017
- JPMA Will Be Watching Discussions on Eligibility Criteria for Companies to Receive Price Maintenance Premium
May 29, 2017
- Suzuki to Serve His 3rd Term as JPWA Chief
May 26, 2017
ページ
With Novartis’ CAR-T therapy Kymriah (tisagenlecleucel) hogging the headlines for its biggest-ever price tag in Japan, many continue to perceive high-price medicines as the main culprit of strained health finances, contending that they are driving up drug spending. But, is…
The workforce in the Japanese pharmaceutical sector is getting leaner and leaner, with the latest securities reports filed by 27 drug makers showing a 1.3% fall in their headcounts in FY2018, or 888 employees. The downtrend has been continuing since…
Riding on the back of an improved regulatory environment in China, major Japanese drug makers are moving to expand their businesses in the world’s second largest pharma market. Companies are pumping up their new drug pipelines, while forging solid sales…
As Japan heralds the new imperial era of Reiwa, Eisai CEO Haruo Naito sat with Jiho to look back on…
Japan’s generic market is hitting a plateau soon. Incentive measures rolled out by the government since 2002 have driven its…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…